Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | HPN | P05981 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.42 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL777854 | 1.00 | KMT2A (0.42) | KMT2AMEN1CYP1A2CYP2D6SLC22A2 | |
| SCHEMBL777902 | 0.98 | KMT2A (0.44) | KMT2AMEN1CYP1A2CYP2D6SLC22A2 | |
| SCHEMBL778261 | 0.98 | KMT2A (0.44) | KMT2AMEN1CYP1A2CYP2D6SLC22A2 | |
| SCHEMBL778010 | 0.98 | KMT2A (0.44) | KMT2AMEN1CYP1A2CYP2D6SLC22A2 | |
| SCHEMBL777926 | 0.98 | KMT2A (0.44) | KMT2AMEN1CYP1A2CYP2D6SLC22A2 | |
| SCHEMBL12592385 | 0.96 | KMT2A (0.43) | KMT2AMEN1CYP1A2CYP2D6SLC22A2 | |
| SCHEMBL777676 | 0.96 | KMT2A (0.43) | KMT2AMEN1CYP1A2CYP2D6SLC22A2 | |
| SCHEMBL12592177 | 0.95 | KMT2A (0.42) | KMT2AMEN1CYP1A2CYP2D6SLC22A2 | |
| SCHEMBL12355706 | 0.95 | KMT2A (0.42) | KMT2AMEN1CYP1A2CYP2D6SLC22A2 | |
| SCHEMBL12592092 | 0.95 | KMT2A (0.41) | KMT2AMEN1CYP1A2CYP2D6SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071618-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071618-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8067068-B2 | Liquid crystal compositions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067068-B2 | Liquid crystal compositions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8044228-B2 | Liquid crystal compositions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044228-B2 | Liquid crystal compositions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100308265-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308269-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308265-A1 | LIQUID CRYSTAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100308269-A1 | LIQUID CRYSTAL COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100308265-A1 | LIQUID CRYSTAL COMPOSITIONS | CNOT9, AQP3, AQP1 | KMT2A 3598/4885MEN1 1865/4885CYP1A2 2235/4885 |
| US-20120071618-A1 | LIQUID CRYSTAL COMPOSITIONS | CNOT9, AQP3, AQP1 | KMT2A 3598/4885MEN1 1865/4885CYP1A2 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.